去纤苷在哪可以买到？

On October 22, 2013, (Defibrotide Sodium) was approved for marketing by the European Union as the first treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation. On March 30, 2016, the U.S. Food and Drug Administration (FDA) approved defibrotide (sodium defibrotide) for the treatment of hepatic veno-occlusive disease (VOD) caused by hematopoietic stem cell transplantation in adults and children with renal and pulmonary dysfunction.

In a phase 2 trial of 75 patients, a phase 3 trial of 102 patients, and an expansion trial of an additional 351 patients, all patients in the trial were diagnosed with hepatic VOD with renal or pulmonary dysfunction after HSCT. In the phase 2 trial, 44% of patients survived 100 days after transplantation, compared with 38% in the phase 3 trial and 45% in the expanded trial, and the FDA noted in a report that the expected 100-day survival rate in patients with severe hepatic VOD who were not treated with defibrotide was 21%-31%.

Based on its anticoagulant, fibrinolysis-promoting, and anti-inflammatory effects, Richardson et al. first explored the application of defibrotide (defibrotide sodium) in the treatment of HVOD after HSCT. This study included 19 sHVOD patients. The dosage of defibrotide is 5~60mg/kg per day, intravenous infusion, and the median usage time is 15d (2-61d). The results showed that 42% of patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%, and patients could tolerate defibrination well. Since then, multiple clinical trials have confirmed the effectiveness of defibrotide in the treatment of HVOD. In terms of safety, the side effects of defibrotide are relatively mild, with only 4% of patients discontinuing treatment due to side effects.

Where can I buy Defibrinoside?

(Defibrotide Sodium) is a prescription drug that has been launched in Turkey. Patients in need can contact the Medical Companion Travel Service to obtain regular drug purchase channels.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: